CSI notes in a press release that the 2.00 Max Crown is uniquely designed to enable simultaneous modification of both intimal and medial calcium. The device features an increased 70-micron diamond coated crown that creates more efficient engagement in mixed plaque, helping to achieve optimal luminal gain in mild to moderately calcified lesions above the knee.
Amit Srivastava (Bay Area Heart Center, St Petersburg, USA), who was one of the first physicians in the USA to incorporate the 2.00 Max Crown into his practice, commented: “The new 2.00 Max Crown greatly expands the lesions that can be treated with CSI’s orbital atherectomy. This device delivers exceptional luminal gain in mixed morphology lesions above the knee.”
Scott R Ward, chairman, president and chief executive officer of CSI, said: “The full commercial launch of the 2.00 Max Crown represents another important product launch for CSI as we broaden and diversify our product offering. Our peripheral orbital atherectomy systems can now treat a wider range of plaque morphologies throughout the leg. Combining this new device with our full line of interventional support devices, we continue to advance the ability of physicians to improve outcomes for patients undergoing peripheral interventions.”